Market Place
Sourcing Support
Catalyst’s Sub-Licensee DyDo Gets Approval for FIRDAPSE in Japan
24 Sep 2024 //
GLOBENEWSWIRE
Catalyst Gets Higher FIRDAPSE® Maximum Dose Approval From FDA
31 May 2024 //
GLOBENEWSWIRE
Catalyst to Participate in the 2024 Cantor Virtual MDS
27 Mar 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
02 Nov 2023 //
GLOBENEWSWIRE
Catalyst Pharma Announces Settlement of U.S. Patent Litigation and Resolution
12 Jul 2022 //
GLOBENEWSWIRE
Serb SA`s Amifampridine Serb (amifampridine) Receives Approval in Europe
25 May 2022 //
EMA
Catalyst Pharma Reports that Ruzurgi`s FDA Marketing Approval is No Longer Valid
03 Feb 2022 //
GLOBENEWSWIRE
Catalyst Pharma Receives Issuance of Mandate by the U.S. Court of Appeals
28 Jan 2022 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study
06 Dec 2021 //
GLOBENEWSWIRE
Enforcement Report - Week of October 6, 2021
06 Oct 2021 //
FDA
Appeals Court Supports Catalyst’s Attempt to Overturn FDA Decision
01 Oct 2021 //
BIOSPACE
Jacobus Pharmaceuticals Issues Voluntary Worldwide Recall of Ruzurgi 10 mg
13 Sep 2021 //
FDA
Health Canada Issues Recall of Medunik`s Ruzurgi (amifampridine)
09 Sep 2021 //
HEALTH CANADA
Catalyst Pharma Comments on Recent Decision by Health Canada for Ruzurgi
28 Jun 2021 //
GLOBENEWSWIRE
Catalyst Pharma Announces Exclusive License & Supply Agreement with DyDo Pharma
28 Jun 2021 //
GLOBENEWSWIRE
Ruzurgi® Now Available to Canadian LEMS Patients
25 Sep 2020 //
NEWSWIRE
Médunik Canada Expands its Orphan Disease Portfolio by Market for Ruzurgi®
18 Aug 2020 //
NEWSWIRE
Judge Recommends Throwing Out Catalyst’s Suit Against FDA
04 Aug 2020 //
FDANEWS
An incensed Catalyst Pharma sues the FDA
13 Jun 2019 //
ENDPTS
Is Jacobus poised to win physician, payer support for off-label adult LEMS use?
11 Jun 2019 //
ENDPTS
Catalyst dives as FDA approves rival`s rare disease drug
08 May 2019 //
BIOPHARMADIVE
FDA approves Ruzurgi for children with Lambert-Eaton myasthenic syndrome
08 May 2019 //
PHARMA TIMES
Catalyst`s $375K Firdapse could get off-label competition
07 May 2019 //
FIERCE PHARMA
Sanders Questions $375,000 Price Tag for Previously Free Drug
04 Jan 2019 //
RAPS
Catalyst will charge $375,000 for rare disease drug
13 Dec 2018 //
STAT NEWS
U.S. FDA approves Catalyst Pharma`s rare disease drug
29 Nov 2018 //
REUTERS
Catalyst Announces FDA Acceptance NDA and Priority Review Status for Firdapse®
29 May 2018 //
GLOBENEWSWIRE
Catalyst Announces Plans to Resubmit New Drug Application for Firdapse®
12 Feb 2018 //
GLOBENEWSWIRE
Catalyst heads back to the FDA in search an elusive OK after Firdapse scores Ph3
28 Nov 2017 //
ENDPTS
Catalyst Announces +ve Top-Line Results, Second Ph3 Clinical Trial of Firdapse®
27 Nov 2017 //
GLOBENEWSWIRE
Catalyst`s Announces Phase 2 Study of Firdapse® Ambulatory Patients with (SMA)
24 Nov 2017 //
GLOBENEWSWIRE
Catalyst Announces Ph2 Study of Firdapse® in Ambulatory Patients with (SMA)
21 Nov 2017 //
GLOBENEWSWIRE
Catalyst Completes Enrollment in Second Phase 3 Trial of Firdapse®
31 Oct 2017 //
GLOBENEWSWIRE
Catalyst Pharma Announces +ve Data from Investigator-Sponsored Trial of Firdapse
15 Mar 2017 //
GLOBENEWSWIRE
BioMarin submits NDA for drisapersen
27 Apr 2015 //
BIOMARIN PHARM
